Von Willebrand’s disease – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 19 Jun 2026 04:03:23 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Von Willebrand’s disease – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A Study of VGA039 to Prevent Bleeding in Teenagers and Adults with von Willebrand Disease Who Have Not Used Regular Preventive Treatment Before https://clinicaltrials.eu/trial/a-study-of-vga039-to-prevent-bleeding-in-teenagers-and-adults-with-von-willebrand-disease-who-have-not-used-regular-preventive-treatment-before/ Wed, 29 Apr 2026 15:08:49 +0000 https://clinicaltrials.eu/trial/a-study-of-vga039-to-prevent-bleeding-in-teenagers-and-adults-with-von-willebrand-disease-who-have-not-used-regular-preventive-treatment-before/ This study is looking at a bleeding disorder called von Willebrand Disease. People with this condition have problems with blood clotting, which means they may experience bleeding episodes more often than usual. The treatment being tested is called VGA039, which is given as an injection under the skin. This medicine is designed to help prevent bleeding from happening in the first place, rather than treating bleeds after they occur.

The purpose of this study is to see how well VGA039 works at reducing the number of bleeding events in people with von Willebrand Disease who have not been using preventive treatment regularly before. The study will also check how safe this medicine is when used over time. During the study, participants will receive regular injections of VGA039 under the skin for a period that can last up to 57 weeks. The doctors will keep track of how many bleeding episodes occur and monitor the overall health of participants throughout the treatment period.

This is a phase 3 study, which means the medicine has already been tested in earlier studies and is now being evaluated in a larger group of people to confirm that it works well and is safe. The study is open-label, which means both the participants and the doctors will know that everyone is receiving the active medicine. Participants will be adolescents and adults with von Willebrand Disease who have experienced frequent bleeding episodes in the past.

]]> Study on the Safety and Effectiveness of Emicizumab for Patients with Type 3 Von Willebrand Disease https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-emicizumab-for-patients-with-type-3-von-willebrand-disease/ Wed, 29 Apr 2026 15:04:48 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-emicizumab-for-patients-with-type-3-von-willebrand-disease/ This clinical trial is focused on studying the effects of a medication called Emicizumab in patients with a rare bleeding disorder known as Type 3 Von Willebrand Disease. This condition is characterized by a severe deficiency of a protein called von Willebrand factor, which is essential for blood clotting. The study aims to evaluate how well Emicizumab works in preventing bleeding episodes when used regularly, compared to the usual treatment that is given only when bleeding occurs.

Participants in the study will receive Emicizumab as a preventive treatment, which means it will be administered on a regular schedule to help prevent bleeding episodes. The study will monitor the number of bleeding events over time, as well as any side effects or reactions to the medication. The trial will also assess the overall safety of Emicizumab and its impact on the participants’ health, including any changes in their physical condition and laboratory test results.

The study will take place over several years, allowing researchers to gather comprehensive data on the long-term effects of Emicizumab in managing Type 3 Von Willebrand Disease. This research is important for understanding how this medication can improve the quality of life for individuals with this challenging condition by reducing the frequency and severity of bleeding episodes.

]]> Study on the Effects of BT200 (Rondaptivon Pegol) for Patients with Type 2B von Willebrand Disease https://clinicaltrials.eu/trial/study-on-the-effects-of-bt200-rondaptivon-pegol-for-patients-with-type-2b-von-willebrand-disease/ Wed, 29 Apr 2026 15:02:27 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-bt200-rondaptivon-pegol-for-patients-with-type-2b-von-willebrand-disease/ This clinical trial is focused on studying the effects of a treatment for Type 2B von Willebrand Disease, a condition that affects blood clotting and can lead to excessive bleeding. The treatment being tested is called Rondaptivon pegol, also known by its code name BT200. This medication is designed to help manage the symptoms of the disease by affecting certain blood components involved in clotting.

The purpose of the study is to evaluate how BT200 impacts platelet count, which are the cells in the blood that help with clotting, as well as other factors related to bleeding. Participants in the study will receive the treatment through an injection under the skin. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects. The study will last for a period of four weeks, during which the effects of the treatment will be closely monitored.

Throughout the study, researchers will observe changes in the number of bleeding events and measure various blood components to understand how BT200 works in the body. This includes looking at how long the medication stays in the body and its effects on specific proteins involved in blood clotting. The study aims to provide valuable information on the safety and effectiveness of BT200 for people with Type 2B von Willebrand Disease.

]]> Study on Preventing Bleeding in Children with Severe von Willebrand Disease Using Vonicog Alfa and Octocog Alfa https://clinicaltrials.eu/trial/study-on-preventing-bleeding-in-children-with-severe-von-willebrand-disease-using-vonicog-alfa-and-octocog-alfa/ Wed, 29 Apr 2026 15:00:17 +0000 https://clinicaltrials.eu/trial/study-on-preventing-bleeding-in-children-with-severe-von-willebrand-disease-using-vonicog-alfa-and-octocog-alfa/ This clinical trial is focused on studying the effectiveness and safety of a treatment for children with a severe form of von Willebrand disease (VWD). VWD is a genetic disorder that affects the blood’s ability to clot properly, leading to excessive bleeding. The treatment being tested is called rVWF, which stands for recombinant von Willebrand factor. This is a lab-made version of a protein that helps blood clot. The study aims to see how well this treatment can prevent bleeding episodes in children with severe VWD.

Participants in the study will receive the treatment rVWF regularly to prevent bleeding. The study will compare the number of bleeding episodes they experience during the study to the number they had before joining the study. This will help determine if the treatment is effective in reducing bleeding. The study will also monitor for any side effects or reactions to the treatment, such as allergic reactions or changes in vital signs.

The study will last for up to 12 months, during which time participants will receive the treatment through an injection into a vein, known as intravenous use. The goal is to gather information on how well the treatment works and how safe it is for children with severe von Willebrand disease. The results will help doctors understand if this treatment can be a reliable option for managing this condition in children.

]]> Study on the Effectiveness and Safety of Vonicog Alfa with or without Octocog Alfa for Children with Severe von Willebrand Disease Experiencing Bleeding or Undergoing Surgery https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-vonicog-alfa-with-or-without-octocog-alfa-for-children-with-severe-von-willebrand-disease-experiencing-bleeding-or-undergoing-surgery/ Wed, 29 Apr 2026 14:28:55 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-vonicog-alfa-with-or-without-octocog-alfa-for-children-with-severe-von-willebrand-disease-experiencing-bleeding-or-undergoing-surgery/ This clinical trial is focused on studying a condition called Severe von Willebrand Disease in children. This is a hereditary bleeding disorder where the blood does not clot properly, leading to excessive bleeding. The study is testing the effectiveness, safety, and tolerability of a treatment called Recombinant Von Willebrand Factor (rVWF), which may be used with or without another medication called Advate. These treatments are given as injections to help control bleeding episodes and to assist during surgeries, whether they are planned or emergencies.

The purpose of the study is to evaluate how well rVWF works in managing bleeding events in children under 18 years old who have severe von Willebrand Disease. The study will also look at how safe the treatment is and how well children tolerate it. Participants in the study will receive the treatment over a period of time, and their response to the treatment will be monitored. Some children may receive a placebo, which is a substance with no active medication, to compare the effects of the treatment.

Throughout the study, researchers will collect information on how effective the treatment is in stopping bleeding, how many doses are needed, and any side effects that may occur. They will also study how the body processes the treatment, which is known as pharmacokinetics. This includes understanding how long the treatment stays in the body and how it is broken down. The study aims to provide valuable information that could improve the management of severe von Willebrand Disease in children.

]]>